View in EDS

Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.

Saved in:
Bibliographic Details
Title: Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.
Authors: Pandya H; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Patel M; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Gillen M; Creek Lane PK, LLC, Waterford, Virginia., Reddy J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, The Discovery Centre, Biomedical Campus, Cambridge, UK., Bednarczyk A; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland., Kokot M; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland., Tan Y; Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Mississauga, Ontario, Canada., Heijer M; Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca, Mölndal, Gothenburg, Sweden., Andersson M; Respiratory and Immunology, Clinical Operations, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg, Sweden., Petullo D; Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Jassal M; Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&D, Gaithersburg, Maryland. Electronic address: mandeep.jassal@astrazeneca.com.
Source: Clinical therapeutics [Clin Ther] 2026 Jan; Vol. 48 (1), pp. 73-80. Date of Electronic Publication: 2025 Dec 04.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-114X
DOI:10.1016/j.clinthera.2025.10.011